Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, on Notice from Nasdaq, Plans to Appeal Delisting

NEW YORK, Dec. 19-Lynx Therapeutics said yesterday that it has received a notice of delisting from Nasdaq, which it plans to appeal.


The company's stock has traded below $1.00 since July 31, meaning that it no longer complies with the Nasdaq listing maintenance standards.


Lynx said in a statement that it will request a hearing from the stock market, and is considering a reverse stock split or transferring its stocks to the Nasdaq SmallCap Market, which has more lenient policies.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.